1. Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs
- Author
-
Behrouz Farhadihosseinabadi, Maryam Nikoonezhad, Masoud Soleimani, Ghazaleh Sankanian, Arezou Sayad, and Mahshid Mehdizadeh
- Subjects
business.industry ,medicine.disease ,Small molecule ,Biological pathway ,MicroRNAs ,Phosphatidylinositol 3-Kinases ,chemistry.chemical_compound ,Oncology ,chemistry ,Cancer cell ,microRNA ,Cancer research ,Humans ,Medicine ,Pharmacology (medical) ,Phosphatidylinositol 3-kinase signaling ,Phosphatidylinositol ,Neoplasm Recurrence, Local ,Signal transduction ,Multiple Myeloma ,business ,Multiple myeloma ,Signal Transduction - Abstract
Multiple myeloma is one of the most hard-to-treat cancers among blood malignancies due to the high rate of drug resistance and relapse. The researchers are trying to find more effective drugs for treatment of the disease. Hence, the use of drugs targeting signaling pathways has become a powerful weapon. Overactivation of phosphatidylinositol 3-kinase signaling pathways is frequently observed in multiple myeloma cancer cells, which increases survival, proliferation, and even drug resistance in such cells. In recent years, drugs that inhibit the mediators involved in this biological pathway have shown promising results in the treatment of multiple myeloma. In the present study, we aimed to introduce phosphatidylinositol 3-kinase signaling inhibitors which include small molecules, herbal compounds, and microRNAs.
- Published
- 2021